8 research outputs found

    Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials

    No full text
    <p><b>Article full text</b></p> <p><br></p> <p>The full text of this article can be found here<b>. </b><a href="https://link.springer.com/article/10.1007/s13555-017-0187-0">https://link.springer.com/article/10.1007/s13555-017-0187-0</a></p><p></p> <p><br></p> <p><b>Provide enhanced content for this article</b></p> <p><br></p> <p>If you are an author of this publication and would like to provide additional enhanced content for your article then please contact <a href="http://www.medengine.com/Redeem/”mailto:[email protected]”"><b>[email protected]</b></a>.</p> <p><br></p> <p>The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.</p> <p><br></p> <p>Other enhanced features include, but are not limited to:</p> <p><br></p> <p>• Slide decks</p> <p>• Videos and animations</p> <p>• Audio abstracts</p> <p>• Audio slides</p

    Additional file 1: of Alteration of the cutaneous microbiome in psoriasis and potential role in Th17 polarization

    No full text
    Figure S1. Box plot shows the average weighted UniFrac distances among samples within each disease state at (a) arm, (b)trunk, (c)leg, (d)axilla, (e)gluteal fold and (f)scalp (*: p-value < 0.05, **: p-value < 0.01***: p-value < 0.001****: p-value < 0.0001). Figure S2. Box plot shows the average weighted UniFrac distances among samples within each disease state in (a) dry and (b)moist skin group (*: p-value < 0.05, **: p-value < 0.01***: p-value < 0.001****: p-value < 0.0001). Figure S3. Relative abundance of P. acnes and S. aureus in each disease state at different body sites. Relative abundance of P. acnes in healthy (red), psoriasis lesional (green), psoriasis non-lesional (blue) skin at (a) different skin sites and (b) different skin types (*: p-val < 0.05, **: p-val < 0.01, ****: p-val < 0.0001). (c) Box plot showing S. aureus abundance in S. aureus high samples. S. aureus high samples were defined as samples with higher S. aureus abundance than the highest S. aureus abundance among the healthy samples (baseline = 0.0068). (d) Bar graph depicts the prevalence of S. aureus high samples at each skin site in psoriasis lesional (blue bars) and psoriasis non-lesional (orange bars) skin. (e) Bacterial species associated with S. aureus high samples (red bars) and S. aureus low samples (green bars). Figure S4. Expression of Th1 components in effector T cells in response to Staphylococcus aureus colonization. The expression of Th1 components (a) T-bet (b) IFNγ and (c)IL-2 are comparable in all experimental groups. Figure S5. Expression of Th2 components in effector T cells in response to Staphylococcus aureus colonization. The expression of Th2 cytokines (a) IL-4 (b) IL-5, (c) IL-13 (d) IL-9 are comparable in all experimental groups. The expression of Th2 promoting transcription factor (e) GATA3 is induced by early colonization of S. aureus (adj. p-value = 1.49e-16); whereas, another Th2 transcription factor (f) STAT6 is not significantly induced. (PDF 405 kb

    Building a Citizen Pscientist: Advancing Patient-Centered Psoriasis Research by Empowering Patients as Contributors and Analysts

    Get PDF
    <p></p><p><b>Article full text</b></p> <p><br></p> <p>The full text of this article can be found here<b>. </b><a href="https://link.springer.com/article/10.1007/s13555-018-0242-5">https://link.springer.com/article/10.1007/s13555-018-0242-5</a></p><p></p><p></p><p> </p><p><br></p> <p><b>Provide enhanced content for this article</b></p> <p><br></p> <p>If you are an author of this publication and would like to provide additional enhanced content for your article then please contact <a href="http://www.medengine.com/Redeem/”mailto:[email protected]”"><b>[email protected]</b></a>.</p> <p><br></p> <p>The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.</p> <p><br></p> <p>Other enhanced features include, but are not limited to:</p> <p><br></p> <p>• Slide decks</p> <p>• Videos and animations</p> <p>• Audio abstracts</p> <p>• Audio slides</p><br><p></p
    corecore